Winnipeg, MB, Canada and 19National Cancer Action Team, Department of Health, London, UK Background: We investigate whether differences in breast cancer survival in six high-income countries can be explained by differences in stage at diagnosis using routine data from population-based cancer registri...
Advanced breast cancer: High-dose chemotherapy and bone marrow autotransplant Ann Intern Med, 108 (1988), pp. 570-574 Google Scholar 3. D.J. Arnold, G.J. Lesnick Survival following mastectomy for stage III breast cancer Am J Surg, 137 (1979), pp. 362-366 Google Scholar 4. H.L. At...
According to American Cancer Society, the 5-year survival rate for stage 3 is about 72%. If you find a suitable treatment, there is still a chance to be successfully treated at Modern Cancer Hospital Guangzhou. Thus, it is essentially important for you to make a right decision for breast ...
Afatinib, an irreversible ErbB-family blocker, could improve the survival of advanced epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer patients (NSCLCm+). This phase II trial (NCT04201756) aimed to assess the feasibility of neoad
An overview of trends in cancer survival over time among children and young adolescents in the Netherlands for the period 1990–2015 is provided in Table 1, overall and by gender, age at diagnosis and ICCC-3 diagnostic (sub)group. In addition to the results for malignant cancers, survival es...
When looking at the survival rate for stage 4 pancreatic cancer, the statistics are even worse. Just 3 percent of people with stage 4 pancreatic cancer will still be alive after five years. However, it's important to note that these numbers are based off historical data and there...
Adjunctive anti-bone resorption therapy has become an important part of multiple myeloma (MM) treatment. Currently, no definite evidence exists that this therapy increases survival. We examined a cohort of 13 of 167 patients (8%) treated with the M-2 protocol who received adjuvant gallium nitrate...
After PSM, both overall survival (OS) (p<0.001) and cancer-specific survival (CSS) (p<0.001) were significantly improved in the immunotherapy group. The median OS (mOS) was 6.0months in the non-immunotherapy group and 8.0months in the immunotherapy group. The 1-, 2-, and 3-year OS ...
factor for overall survival in early stage colon cancer. Patients with increased delta-NLR had an favourable clinical outcome. Introduction Colon cancer remained one of the most common cancer and the leading cause of cancer-related mortality worldwide, with an increased incidence1,2,3. Previously,...
to a statistically significant and clinically meaningful improvement in progression-free survival (PFS) vs placebo in patients with locally advanced, unresectable, stage III non–small cell lung cancer (NSCLC) harboring an EGFR mutation, according to data from the phase 3 LAURA trial (NCT03521154)....